Zenitar Biomedical Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • IPO Registration

  • Employees
  • 71

Employees

  • Latest Deal Type
  • IPO
  • (Announced)

  • Investors
  • 26

Zenitar Biomedical General Information

Description

Developer of innovative biopharmaceutical technologies designed to accelerate the discovery and commercialization of new drugs. The company offers comprehensive drug R&D platform covering target research, molecule design, preclinical evaluation, and clinical development, supported by resources from the State Key Laboratory of Biotherapy and Guizhou Bailing Group, thereby helping healthcare providers and patients access advanced therapies, enabling breakthroughs in disease treatment and improved clinical outcomes.

Contact Information

Website
www.zenitar.com.cn
Ownership Status
In IPO Registration
Financing Status
Venture Capital-Backed
Corporate Office
  • Floors 8-10, Building E3
  • Frontier Medical Center
  • Chengdu, Sichuan 610000
  • China
+86 028
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • Floors 8-10, Building E3
  • Frontier Medical Center
  • Chengdu, Sichuan 610000
  • China
+86 028

Zenitar Biomedical Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Zenitar Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. IPO 13-Jan-2026 Announced Generating Revenue
9. Secondary Transaction - Private 01-Jan-2026 Completed Generating Revenue
8. Later Stage VC (Series C) 14-Nov-2025 Completed Generating Revenue
7. Secondary Transaction - Private 30-Oct-2025 Completed Generating Revenue
6. Later Stage VC (Series B1) 24-Jan-2025 Completed Generating Revenue
5. Early Stage VC (Series B) 25-Nov-2023 Completed Clinical Trials - Phase 3
4. Secondary Transaction - Private 15-Oct-2022 Completed Generating Revenue
3. Secondary Transaction - Private 01-Jul-2022 Completed Generating Revenue
2. Early Stage VC (Series A) 07-Dec-2021 $14.9M $14.9M Completed Generating Revenue
1. Seed Round 29-Apr-2019 Completed Startup
To view Zenitar Biomedical’s complete valuation and funding history, request access »

Zenitar Biomedical Patents

  • 68

    Total Documents Applications and Grants

  • Total Patents Families

  • 27

    Granted

  • 25

    Pending

  • Expiring in next 12 mo

Zenitar Biomedical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026219387-A1 Isotopologue of 2,4-disubstituted pyrimidine derivative and use thereof Pending 18-Apr-2025
WO-2026219355-A1 Use of 2,4-disubstituted pyrimidine derivative and combination drug thereof in preparation of drug for preventing and treating hemophagocytic lymphohistiocytosis Pending 18-Apr-2025
WO-2026214551-A1 Alkynyl-substituted fused bicyclic compounds and use thereof Pending 07-Apr-2025
WO-2026201096-A1 Improved solid-state form of triazine compound, preparation method therefor, pharmaceutical composition, and use Pending 26-Mar-2025
WO-2026184712-A1 Preparation method for heterocyclic compound, and intermediate thereof Pending 07-Mar-2025
To view Zenitar Biomedical’s complete patent history, request access »

Zenitar Biomedical Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Zenitar Biomedical Investors (26)

Investor Name Investor Type Holding Investor Since Participating Rounds
Lanchi Ventures Venture Capital Minority
Shanghai Science and Technology Innovation Center Equity Investment Fund Management Fund of Funds Minority
Tencent Investment Corporate Venture Capital Minority
Xiamen C&D Corporation Corporation Minority
Zhuhai Huajin Capital Corporation Minority
You’re viewing 5 of 26 investors. Get the full list »

Ready to get started?

Request a free trial

Zenitar Biomedical FAQs

  • When was Zenitar Biomedical founded?

    Zenitar Biomedical was founded in 2019.

  • Where is Zenitar Biomedical headquartered?

    Zenitar Biomedical is headquartered in Chengdu, China.

  • What is the size of Zenitar Biomedical?

    Zenitar Biomedical has 71 total employees.

  • What industry is Zenitar Biomedical in?

    Zenitar Biomedical’s primary industry is Drug Discovery.

  • Is Zenitar Biomedical a private or public company?

    Zenitar Biomedical is a Private company.

  • What is Zenitar Biomedical’s current revenue?

    The current revenue for Zenitar Biomedical is .

  • How much funding has Zenitar Biomedical raised over time?

    Zenitar Biomedical has raised $175M.

  • Who are Zenitar Biomedical’s investors?

    Lanchi Ventures, Shanghai Science and Technology Innovation Center Equity Investment Fund Management, Tencent Investment, Xiamen C&D Corporation, and Zhuhai Huajin Capital are 5 of 26 investors who have invested in Zenitar Biomedical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process